Aldeyra Therapeutics, Inc. (ALDX) Stock Price & Analysis
Aldeyra Therapeutics, Inc. (ALDX) fell 1.94% to USD 1.52 as of July 25, 2026 at 04:49 UTC, according to Nexqual real-time market data.
ALDX last closed at USD 1.55; the session ranged USD 1.48–1.57 on volume of 1,122,228 shares. Market capitalization is $91.69M, with a 52-week range of USD 1.07–6.18 (NCM). Source: Nexqual, July 25, 2026 at 04:49 UTC.
Key Statistics (as of July 25, 2026 at 04:49 UTC)
| Price | USD 1.52 |
|---|---|
| Change | ▼ 1.94% (down) |
| Previous Close | USD 1.55 |
| Open | USD 1.57 |
| Day Range | USD 1.48 – 1.57 |
| 52-Week Range | USD 1.07 – 6.18 |
| Volume | 1,122,228 shares |
| Market Cap | $91.69M |
| Exchange | NCM |
Technical Analysis (ALDX)
Nexqual's technical model rates ALDX "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 04:49 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 36.41 (neutral) |
| vs SMA50 | Below (USD 1.83) |
| MACD | -0.08 (negative) |
Analyst Ratings (ALDX)
Wall Street analysts rate ALDX "Strong Buy" based on 6 analysts, with a mean price target of USD 7.17 (range USD 2–13), per Nexqual as of July 25, 2026 at 04:49 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 7.17 |
| High Target | USD 13 |
| Low Target | USD 2 |
| Buy / Hold / Sell | 5 / 1 / 0 |
Earnings (ALDX)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.08 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.06 vs est -0.12 ▲ beat |
| 2025-12-31 | USD -0.1 vs est -0.15 ▲ beat |
| 2025-09-30 | USD -0.13 vs est -0.16 ▲ beat |
| 2025-06-30 | USD -0.16 vs est -0.19 ▲ beat |
Source: Nexqual, July 25, 2026 at 04:49 UTC.
Financials & Fundamentals (ALDX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -51.76% |
| Debt / Equity | 36.8 |
| Current Ratio | 2.72 |
| Total Cash | $65.00M |
| Total Debt | $15.51M |
| Free Cash Flow | $-19.60M |
Source: Nexqual, July 25, 2026 at 04:49 UTC.
Financial Health Score (ALDX)
Nexqual rates Aldeyra Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 04:49 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $65M cash vs $16M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$26M |
| Efficiency | Critical — ROE -52%, ROA -22.2% |
Ownership (ALDX)
| Insider Ownership | +3.60% |
|---|---|
| Institutional Ownership | +62.75% |
| Shares Outstanding | 60.32M |
| Float | 52.68M |
| Short % of Float | +9.72% |
Source: Nexqual, July 25, 2026 at 04:49 UTC.
Leadership (ALDX)
Aldeyra Therapeutics, Inc. is led by Todd C. Brady (age 53), CEO, President & Director, per Nexqual as of July 25, 2026 at 04:49 UTC.
| CEO, President & Director | Todd C. Brady (age 53) |
|---|---|
| Director of Translational Sciences & Non-Clinical Development | Adam Lazorchak |
Major Backers & Investors (ALDX)
Notable institutional backers of Aldeyra Therapeutics, Inc. include Knoll Capital Management, LLC, AQR Capital Management, LLC, Kingdon Capital Management LLC, according to Nexqual as of July 25, 2026 at 04:49 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Knoll Capital Management, LLC | 9.08% |
| AQR Capital Management, LLC | 4.69% |
| Kingdon Capital Management LLC | 3.57% |
| 683 Capital Management LLC | 2.49% |
| Shaw D.E. & Co., Inc. | 2.33% |
| Millennium Management | 1.65% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.05% |
| Vanguard Group | 9% |
| Geode Capital | 2.07% |
| State Street | 1.86% |
Source: Nexqual, July 25, 2026 at 04:49 UTC.
From Aldeyra Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-27)
Key Strengths & Strategy (as disclosed to the SEC)
- Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases.
- Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.
- The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication.
- In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ARDX | Ardelyx, Inc. | USD 5.03 | ▼ 0.98% |
| ACRS | Aclaris Therapeutics, Inc. | USD 5.23 | ▼ 6.94% |
| AKBA | Akebia Therapeutics, Inc. | USD 1.22 | ▼ 3.17% |
| AFMDQ | Affimed N.V. | USD 0 | ▲ 0% |
| ATRA | Atara Biotherapeutics, Inc. | USD 7.9 | ▼ 2.77% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 04:49 UTC. This page is informational and not investment advice.